Vaughan Nelson Investment Management L.P. Buys Shares of 1,800,440 ADMA Biologics Inc $ADMA

Vaughan Nelson Investment Management L.P. purchased a new position in ADMA Biologics Inc (NASDAQ:ADMA) during the second quarter, Holdings Channel.com reports. The firm purchased 1,800,440 shares of the biotechnology company’s stock, valued at approximately $32,786,000.

A number of other hedge funds have also modified their holdings of the stock. Ameritas Advisory Services LLC acquired a new position in shares of ADMA Biologics in the second quarter worth $46,000. Mirae Asset Global Investments Co. Ltd. increased its stake in shares of ADMA Biologics by 16.6% in the second quarter. Mirae Asset Global Investments Co. Ltd. now owns 9,222 shares of the biotechnology company’s stock worth $168,000 after acquiring an additional 1,312 shares during the last quarter. State of Alaska Department of Revenue increased its stake in shares of ADMA Biologics by 8.5% in the second quarter. State of Alaska Department of Revenue now owns 142,072 shares of the biotechnology company’s stock worth $2,586,000 after acquiring an additional 11,091 shares during the last quarter. Dakota Wealth Management acquired a new position in shares of ADMA Biologics in the second quarter worth $231,000. Finally, Sheets Smith Wealth Management acquired a new position in shares of ADMA Biologics in the second quarter worth $349,000. 75.68% of the stock is owned by institutional investors and hedge funds.

ADMA Biologics Stock Up 0.9%

NASDAQ ADMA opened at $14.66 on Friday. The company has a debt-to-equity ratio of 0.21, a quick ratio of 2.78 and a current ratio of 5.33. The firm has a 50-day simple moving average of $16.76 and a 200 day simple moving average of $18.75. ADMA Biologics Inc has a twelve month low of $13.50 and a twelve month high of $25.67. The stock has a market cap of $3.50 billion, a PE ratio of 17.05 and a beta of 0.47.

ADMA Biologics (NASDAQ:ADMA) last announced its quarterly earnings results on Wednesday, August 6th. The biotechnology company reported $0.15 EPS for the quarter, topping analysts’ consensus estimates of $0.14 by $0.01. The firm had revenue of $121.98 million during the quarter, compared to analysts’ expectations of $121.77 million. ADMA Biologics had a net margin of 44.06% and a return on equity of 41.01%. The company’s revenue for the quarter was up 13.8% compared to the same quarter last year. During the same quarter last year, the company earned $0.13 earnings per share. On average, research analysts forecast that ADMA Biologics Inc will post 0.51 EPS for the current year.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings reaffirmed a “buy (b-)” rating on shares of ADMA Biologics in a research note on Saturday, September 27th. One investment analyst has rated the stock with a Strong Buy rating and three have given a Buy rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of “Buy” and a consensus price target of $27.67.

ADMA Biologics Company Profile

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.